Amplifon stock forecast: H1 growth and margin outlook
Amplifon is an Italian hearing-care company listed on Borsa Italiana. Its pending GN Hearing acquisition remains a key focus as investors assess potential effects on growth, margins and debt. Explore third-party AMP price targets. Past performance is not a reliable indicator of future results.
Amplifon S.p.A. (AMP) is trading near €11.60 at 8:55am UTC on 7 September 2026, within an intraday range of €11.55–€11.97. Past performance is not a reliable indicator of future results.
Investors remain focused on Amplifon's pending acquisition of GN Hearing assets from GN Store Nord. Management says the deal remains on track, but its impact on margins, debt and revenue growth will depend on execution (ad-hoc-news, 3 September 2026). Successful integration and expected synergies could support sentiment, while higher costs, weaker returns or integration challenges could weigh on it.
Amplifon's first-half 2026 results also shape the outlook. Second-quarter organic revenue growth reached 4.7%, the strongest pace in around two years according to the company, while the adjusted EBITDA margin reached 25.8% (ad-hoc-news, 2 September 2026). Trading volume on 4 September was roughly 706,651 shares on Borsa Italiana, as the FTSE MIB continued to trade sideways in early September (ad-hoc-news, 4 September 2026).
Amplifon stock outlook: GN Hearing deal and analyst targets
As of 7 September 2026, third-party Amplifon stock predictions indicate a range of possible outcomes over the next 12 months. Expectations largely centre on the GN Hearing integration, organic growth and margin performance.
Intesa Sanpaolo
Intesa Sanpaolo forecasts that Amplifon shares could reach €14.70 over the next 12 months. The bank upgraded the stock to buy from neutral but lowered its target from €17, suggesting a more positive view of earnings delivery alongside a lower valuation multiple applied to forward estimates (MarketScreener, 21 August 2026).
Sector consensus
A consensus tracker covering 16 sell-side contributors puts the average 12-month price target at €13.44, around 13.45% above the reference share price used in the snapshot. The forecasts reflect differing views on future earnings and potential synergies from the GN Hearing transaction (ad-hoc-news, 22 August 2026).
Morgan Stanley
Morgan Stanley initiated coverage of Amplifon with an overweight rating and a €14.90 12-month price target. The bank expects the hearing-aid market to grow by around 5% over the next 12–18 months and sees Amplifon as potentially benefiting from a recovery in unit demand (MarketScreener, 3 September 2026).
MarketScreener consensus
MarketScreener's latest consensus data shows an average 12-month price target of €13.53 across 16 analysts, with forecasts ranging from €11 to €16.70. Its consensus classification is outperform, with the average target around 14.4% above the €11.83 reference price used in the update (MarketScreener, 6 September 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
Amplifon earnings: latest results and upcoming date
Amplifon last reported results on 30 July 2026, covering the second quarter and first half of the year (Amplifon Corporate, 30 July 2026).
- H1 2026 revenue reached €1,185.7m, up 1.3% at constant exchange rates, while organic growth accelerated to 3.5%.
- Second-quarter organic growth reached 4.7%, which Amplifon described as its strongest quarterly rate in roughly two years.
- Adjusted EBITDA reached €298.0m in the first half, up 3.6% year on year, while the adjusted EBITDA margin increased by 70 basis points to 25.1%. The second-quarter margin reached 25.8%.
- Adjusted net profit increased 12.3% to €101.6m, while adjusted free cash flow rose 70% year on year to €68.0m.
- Reported EBITDA was affected by one-off costs related to the proposed GN Hearing acquisition and restructuring under Amplifon's Fit4Growth programme
The figures provide two sides to the earnings picture. Improving organic growth and adjusted margins could support expectations for the business if those trends continue. Conversely, acquisition-related spending, restructuring costs or weaker growth could put pressure on future profitability.
According to Amplifon's 2026 financial calendar, its next scheduled release is the third-quarter and nine-month report on 29 October 2026. As of 7 September 2026, the company has not scheduled an interim trading update before that date (Amplifon Corporate, 29 October 2026).
AMP stock price: technical overview
As of 8:55am UTC on 7 September 2026, the AMP stock price trades near €11.60. The share price sits below its 20-day simple moving average (SMA) of roughly €12.08 but above the 50-, 100- and 200-day SMAs at around €11.44, €10.90 and €11.58, respectively .
This creates a mixed technical picture. Trading below the 20-day SMA may indicate weaker short-term momentum, while remaining above the longer-period averages could suggest that recent weakness has not yet extended across all timeframes.
The 200-day exponential moving average (EMA) sits higher at around €12.21, above both the current price and the corresponding 200-day SMA .
Momentum indicators are similarly mixed. The 14-day relative strength index (RSI) is near 44, within neutral territory, while the 14-day average directional index (ADX) is around 18, suggesting relatively limited trend strength (TradingView, TradingView).
The classic pivot point sits near €12.13, with resistance levels at R1 around €12.68 and R2 near €13.24. Below the current price, S1 at around €11.57 provides the closest pivot reference, while the 100-day SMA near €10.90 offers another lower technical level .
A move above nearby resistance could shift attention towards higher technical levels, while a move below support could bring lower reference points into focus. Technical indicators can change quickly and should not be used in isolation to predict future price movements (TradingView, 7 September 2026).
This is technical analysis for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.
Amplifon share price history (2024–2026)
AMP’s stock price stood at €28.47 on 9 September 2024 before declining through late 2024 and early 2025. By 6 March 2025, the stock had fallen to €20.62 from a €24.21 close the previous day.
Another sharp move came in March 2026. Amplifon fell from €9.05 on 16 March to €8.09 on 17 March, alongside the announcement of its €2.3bn agreement to acquire GN Store Nord's hearing business.
The transaction created competing considerations for investors. A larger combined business and potential synergies could support Amplifon's longer-term earnings if the acquisition performs as expected. At the same time, financing requirements, potential dilution and integration costs could put pressure on profitability or investor sentiment.
The stock reached a two-year low near €8.03 on 18 March 2026 before recovering during the spring and summer.
Amplifon closed at €11.22 on 30 July and briefly reached €12.62 on 14 August following its half-year results. Amplifon was trading at €11.61 on 7 September 2026, around 16.7% lower year to date and 59.2% lower year on year.
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Amplifon (AMP): Capital.com analyst view
Amplifon's share-price performance over the past year has largely reflected changing expectations around the proposed GN Hearing acquisition and the company's underlying operating performance.
The March 2026 acquisition announcement was followed by a sharp fall in the shares as investors assessed the size and financing of the deal. Since then, the stock has recovered part of those losses, while analysts have continued to weigh its potential benefits against the associated risks.
If Amplifon delivers the expected synergies, maintains organic growth and integrates GN Hearing effectively, the transaction could improve the group's scale and earnings potential over time. A stronger hearing-aid market could also support revenue growth.
However, the opposite scenario remains possible. Higher integration or restructuring costs, weaker demand, margin pressure or slower-than-expected synergy delivery could weigh on earnings and potentially on the share price.
Amplifon's first-half results added another layer to the outlook. Organic growth accelerated and adjusted margins improved, but reported profitability included one-off costs. That means future performance will depend not only on headline growth but also on how effectively the company manages costs, margins and the GN Hearing transaction.
Overall, Amplifon's share price reflects a balance between potential longer-term benefits from greater scale and near-term risks around execution, financing and profitability. Which factors have the greatest influence may change as the acquisition progresses and new financial results become available.
Summary – Amplifon 2026
- As of 8:55am UTC on 7 September 2026, Amplifon was trading near €11.60, within an intraday range of €11.55–€11.97.
- According to TradingView data, technical indicators present a mixed picture. The price is below the 20-day SMA but above its 50-, 100- and 200-day SMAs, while the RSI sits in neutral territory near 44.
- The proposed GN Hearing acquisition remains a central influence. Successful integration and synergies could support longer-term earnings, while financing, margin and execution risks could weigh on performance.
- Amplifon's second-quarter organic growth reached 4.7%, while its adjusted EBITDA margin reached 25.8%.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Amplifon stock?
The article doesn’t identify Amplifon’s largest shareholder, so it would be better not to state one without a separate ownership source. Shareholder positions can also change over time as institutional investors adjust their holdings. For an up-to-date view, investors can check Amplifon’s latest company filings or shareholder disclosures, which may show major strategic, institutional or insider holdings.
What is the five-year Amplifon share price forecast?
The article doesn’t provide a five-year AMP stock forecast. The third-party estimates it covers focus mainly on a 12-month horizon, with recent analyst targets ranging from €11 to €16.70. Longer-term forecasts become increasingly uncertain because they depend on variables such as demand, margins, competition and the GN Hearing integration. Predictions can change substantially as new financial results and market information emerge.
Is Amplifon a good stock to buy?
Whether Amplifon is a suitable stock depends on an individual’s objectives, risk tolerance and wider portfolio, so the article doesn’t classify it as a good or bad investment. Analysts currently hold differing views on its prospects. Potential positives include organic growth, margin improvement and possible GN Hearing synergies, while integration costs, financing pressures, weaker demand or slower-than-expected earnings growth could weigh on performance.
Could Amplifon stock go up or down?
Yes. Amplifon shares could move in either direction as investors respond to new information. Stronger organic growth, improved margins or successful GN Hearing integration could support the price, while weaker demand, higher costs, financing concerns or disappointing synergy delivery could put pressure on it. Technical levels may also influence shorter-term trading behaviour, although indicators can change quickly and don’t reliably predict future price movements.
Should I invest in Amplifon stock?
The article doesn’t recommend whether to invest in Amplifon. Any decision would depend on factors such as your financial circumstances, objectives, time horizon and tolerance for risk. Amplifon currently presents both potential opportunities and risks, particularly around growth, margins and the proposed GN Hearing acquisition. Investors may wish to consider company fundamentals, valuation, market conditions and their own risk profile before making any decision.
Can I trade Amplifon CFDs on Capital.com?
Yes, you can trade Amplifon CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.